SDC4, syndecan 4, 6385

N. diseases: 71; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.310 Biomarker disease CTD_human Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. 22919003 2012
CUI: C0007131
Disease: Non-Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma 		0.310 GeneticVariation disease BEFREE A biopsy acquired after disease progression revealed the original SDC4-ROS1 fusion along with a KRAS point mutation (p.G12D).We reviewed the related literature to determine the frequency of gene mutations in non-small cell lung cancer patients. 28971587 2018
CUI: C0018801
Disease: Heart failure
Heart failure 		0.040 Biomarker disease BEFREE Syndecan-4, a transmembrane heparan sulfate proteoglycan, is essential for pathological remodeling, and we here investigated its expression and shedding during heart failure. 23374111 2013
CUI: C0018801
Disease: Heart failure
Heart failure 		0.040 AlteredExpression disease BEFREE Increased syndecan-4 levels were previously detected after acute myocardial infarction and in subjects with heart failure. 29232393 2017
CUI: C0018801
Disease: Heart failure
Heart failure 		0.040 Biomarker disease BEFREE Circulating shed syndecan-4 is increased in heart failure patients, however the pathophysiological and molecular consequences associated with syndecan-4 shedding remain poorly understood. 26449522 2015
CUI: C0018801
Disease: Heart failure
Heart failure 		0.040 Biomarker disease BEFREE Our data suggest that syndecan-4 is essential for the compensated hypertrophy and the maintenance of cardiac function during the process of heart failure following pressure overload. 28395201 2017
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure 		0.040 AlteredExpression disease BEFREE Increased syndecan-4 levels were previously detected after acute myocardial infarction and in subjects with heart failure. 29232393 2017
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure 		0.040 Biomarker disease BEFREE Circulating shed syndecan-4 is increased in heart failure patients, however the pathophysiological and molecular consequences associated with syndecan-4 shedding remain poorly understood. 26449522 2015
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure 		0.040 Biomarker disease BEFREE Our data suggest that syndecan-4 is essential for the compensated hypertrophy and the maintenance of cardiac function during the process of heart failure following pressure overload. 28395201 2017
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure 		0.040 Biomarker disease BEFREE Syndecan-4, a transmembrane heparan sulfate proteoglycan, is essential for pathological remodeling, and we here investigated its expression and shedding during heart failure. 23374111 2013
CUI: C0029408
Disease: Degenerative polyarthritis
Degenerative polyarthritis 		0.040 AlteredExpression disease BEFREE This study revealed that the cartilage protective effect of osthole in a MIA-induced osteoarthritis (OA) murine model can be explained by downregulation of COX-2 and RUNX2 by inhibition of NF-κB and HIF-2α up-regulated by OA induction, resulting in downregulation of MMP-13, Syndecan IV and ADAMTS-5. 31765607 2020
CUI: C0029408
Disease: Degenerative polyarthritis
Degenerative polyarthritis 		0.040 AlteredExpression disease BEFREE Both VEGF and syndecan-4 are expressed by chondrocytes and both are involved in the regulation of matrix metalloproteinase-3, resulting in the activation of aggrecanase II (ADAMTS-5), which is essential in the pathogenesis of OA. 25274915 2014
CUI: C0029408
Disease: Degenerative polyarthritis
Degenerative polyarthritis 		0.040 Biomarker disease BEFREE Using an immunoassay for the extracellular domain of syndecan-4, we found 68% of the syndecan-4 in the culture supernatant of OA chondrocytes culture, suggesting that a large majority of the syndecan-4 is shed and released in the extracellular medium. 31455087 2019
CUI: C0029408
Disease: Degenerative polyarthritis
Degenerative polyarthritis 		0.040 Biomarker disease BEFREE Our data suggest that strategies aimed at the inhibition of syndecan-4 will be of great value for the treatment of cartilage damage in osteoarthritis. 19684582 2009
CUI: C0003507
Disease: Aortic Valve Stenosis
Aortic Valve Stenosis 		0.020 Biomarker disease BEFREE For a similar severity of AS, male patients demonstrated higher indexed left ventricular (LV) volumes and mass, more concentric remodeling (higher LV mass/volume), a trend to more late gadolinium enhancement (present in 51.1% men vs. 34.1% women; p = 0.057), and higher extracellular volume index than female patients (13.27 [interquartile range (IQR): 11.5 to 17.0] vs. 11.53 [IQR: 10.5 to 13.5] ml/m<sup>2</sup>, p = 0.017), with worse systolic and diastolic function and higher MMP-3 and syndecan-4 levels, whereas female patients had higher septal E/e'. 29248646 2019
CUI: C0003507
Disease: Aortic Valve Stenosis
Aortic Valve Stenosis 		0.020 AlteredExpression disease BEFREE Finally, patients with hypertrophic myocardium due to aortic stenosis had increased syndecan-4 levels with decreased pS179 which was associated with increased NFAT activation. 22164265 2011
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.020 Biomarker disease BEFREE No association was found with SDC4 and breast cancer in our population. 25361632 2015
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.020 Biomarker disease BEFREE Sulfated Glycoaminoglycans and Proteoglycan Syndecan-4 Are Involved in Membrane Fixation of LL-37 and Its Pro-Migratory Effect in Breast Cancer Cells. 31547381 2019
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction 		0.020 Biomarker disease BEFREE Gender differences in the association of syndecan-4 with myocardial infarction: The population-based Tromsø Study. 30278359 2018
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction 		0.020 AlteredExpression disease BEFREE Here we explored the therapeutic potential of sustained synd4 over-expression in the context of myocardial infarction. 22561100 2012
CUI: C0032285
Disease: Pneumonia
Pneumonia 		0.020 Biomarker disease BEFREE Addition of both suPAR and syndecan-4 to the Pneumonia Severity Index significantly improved their prognostic accuracy, with an AUC of 0.885. 29368632 2018
CUI: C0032285
Disease: Pneumonia
Pneumonia 		0.020 Biomarker disease BEFREE The authors have previously demonstrated syndecan-4's critical roles in pulmonary inflammation. 31600983 2019
CUI: C0155626
Disease: Acute myocardial infarction
Acute myocardial infarction 		0.020 AlteredExpression disease BEFREE In this study, we measured plasma levels of syndecan-4 in patients with acute myocardial infarction using an enzyme-immunoassay, and found that they were extremely high, with a peak of average (10.5 +/- 5.6 ng/ml, 2 weeks after onset), as compared with those in normal subjects (0.078 +/- 0.030 ng/ml) (p < 0.001). 11372670 2001
CUI: C0155626
Disease: Acute myocardial infarction
Acute myocardial infarction 		0.020 AlteredExpression disease BEFREE Increased syndecan-4 levels were previously detected after acute myocardial infarction and in subjects with heart failure. 29232393 2017
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 Biomarker disease BEFREE No association was found with SDC4 and breast cancer in our population. 25361632 2015